Northpond Ventures is a multi-billion-dollar science-driven venture capital firm that builds and supports breakthrough science and technology driven businesses to create a marked impact on humanity. The firm is an active lead life science investor with offices in Cambridge, MA; San Francisco, CA; and Bethesda, MD.
42% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $58.7M (across 115 rounds with reported amounts).
Portfolio
84
Fund Size
—
Top Stage
Series A
Last 12 Mo
6
Team
AJ
Andrea Jackson
Partner
PS
Pat Smerkers, CPA
Chief Financial Officer, Partner
TS
Tim Schmidt, CPA, CFA
Vice President, Fund Finance
BH
Ben Hartheimer
Senior Associate, Portfolio Operations
SY
Stephanie Yan
Senior Associate
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
138 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 OMass Therapeutics | Series C | $310M | Oct 2026 |
 Mestag Therapeutics Limited | Series B | $40M | Mar 2026 |
 VieCure | Series A | $43M | Jan 2026 |
 Vizgen | Series C | $48M | Jan 2026 |
 Mestag Therapeutics | Seed | $95M | Jan 2026 |
 Mestag Therapeutics | Seed | $95M | Jan 2026 |
 Culture Biosciences | Series C | — | Dec 2025 |
 Elephas | Series B | $40M | Nov 2025 |
 Elephas | Series B | $40M | Nov 2025 |
| EEpigenic Therapeutics | Series B | $60M | Sep 2025 |
 Epigenic | Series B | $60M | Sep 2025 |
| GGaruda Therapeutics | Series A | $50M | Mar 2025 |
 ENPLUSONE BIO | Seed | $10M | Feb 2025 |
 Eleanor Health | Series C | $30M | Oct 2024 |
| Elephas | Series C | $55M | Jan 2024 |
| Elephas | Series C | $55M | Jan 2024 |
 Vigil Neuroscience | Series A | $50M | Jan 2024 |
| VieCure | Series C | $45M | Jan 2024 |
| Eleanor Health | Series D | — | Jan 2024 |
 Totus Medicines | Series B | $66M | Dec 2023 |
 Aro Biotherapeutics | Series B | $41.5M | Nov 2023 |
| KKyverna Therapeutics | Series B | $60M | Aug 2023 |
 Vital Bio | Series A | — | Jul 2023 |
 Refeyn | Series B | — | Apr 2023 |
| Vigil Neuroscience | Series B | $90M | Jan 2023 |
Page 1 of 6
Top Co-Investors
Sands Capital16 shared
ARCH Venture Partners16 shared
OrbiMed14 shared
GV12 shared
Rock Springs Capital12 shared
Alexandria Venture Investments11 shared
Cowen Healthcare Investments11 shared
Khosla Ventures10 shared
Tao Capital Partners10 shared
Windham Capital Partners10 shared
Foresite Capital9 shared
S328 shared
SV Health Investors8 shared
Illumina Ventures8 shared
Perceptive Advisors7 shared
Cormorant Asset Management7 shared
Menlo Ventures7 shared
AV8 Ventures7 shared
Alumni Ventures7 shared
Moore Strategic Ventures6 shared
Last updated: 20 October 2026